Literature DB >> 21848990

Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses.

Cynthia M Nijenhuis1, Peter G J ter Horst, Nienke van Rein, Bob Wilffert, Lolkje T W de Jong-van den Berg.   

Abstract

AIMS: Antidepressant use has increased in the last decade. Several studies have suggested a possible association between maternal antidepressant use and teratogenic effects.
METHODS: The pharmacy prescription database IADB.nl was used for a cohort study in which laxative and antidiarrhoeal medication use in children after in utero exposure to antidepressants (TCA, SSRI, fluoxetine or paroxetine exposed) was compared with no antidepressant exposure. Laxatives and antidiarrhoeal medication use were applied as a proxy for constipation and diarrhoea respectively, which may be associated with disturbed enteric nervous system (ENS) development.
RESULTS: Children exposed in utero to SSRIs (mainly fluoxetine and paroxetine) in the second and third trimester or to TCAs in the first trimester, more often received laxatives. Combined exposure to TCAs and SSRIs in pregnancy was associated with a 10-fold increase in laxative use. In utero exposure to SSRIs is not associated with antidiarrhoeal medication use compared with non-exposed children. In contrast, antidiarrhoeal medication use was significantly higher in children exposed to TCAs anytime in pregnancy.
CONCLUSIONS: The increased laxative use after second and third trimester exposure to SSRIs might be explained through the inhibitory effect of the serotonin re-uptake transporter (SERT) and because of selectivity for the 5-HT(2B) receptor which affects the ENS. TCA exposure during the first trimester leads to increased laxative use probably through inhibition of the norepinephrine transporter (NET). Exposure of TCAs anytime in pregnancy leads to increase diarrhoeal use possibly through down-regulation of α₂-adrenoceptors or up-regulation of the pore forming α(1c) subunit.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21848990      PMCID: PMC3248262          DOI: 10.1111/j.1365-2125.2011.04081.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  47 in total

1.  Neonatal complications after intrauterine exposure to SSRI antidepressants.

Authors: 
Journal:  Prescrire Int       Date:  2004-06

2.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.

Authors:  Carol Louik; Angela E Lin; Martha M Werler; Sonia Hernández-Díaz; Allen A Mitchell
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

Review 3.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Psychotropics in pregnancy: weighing the risks.

Authors:  Sandeep Grover; Ajit Avasthi; Yogesh Sharma
Journal:  Indian J Med Res       Date:  2006-04       Impact factor: 2.375

5.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

6.  Role of alpha-2 adrenergic receptors in the control of diarrhea and intestinal motility.

Authors:  N S Doherty; A A Hancock
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

Review 7.  The safety of antidepressant drugs during pregnancy.

Authors:  Bengt Källén
Journal:  Expert Opin Drug Saf       Date:  2007-07       Impact factor: 4.250

Review 8.  Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.

Authors:  Benjamin Bar-Oz; Thomas Einarson; Adrienne Einarson; Radinka Boskovic; Lisa O'Brien; Heli Malm; Anick Bérard; Gideon Koren
Journal:  Clin Ther       Date:  2007-05       Impact factor: 3.393

9.  Luminal adrenergic agents modulate ileal transport: discrimination between alpha 1 and alpha 2 receptors.

Authors:  M K Barry; J D Aloisi; S P Pickering; C J Yeo
Journal:  Am J Surg       Date:  1994-01       Impact factor: 2.565

10.  Distinct subpopulations of enteric neuronal progenitors defined by time of development, sympathoadrenal lineage markers and Mash-1-dependence.

Authors:  E Blaugrund; T D Pham; V M Tennyson; L Lo; L Sommer; D J Anderson; M D Gershon
Journal:  Development       Date:  1996-01       Impact factor: 6.868

View more
  14 in total

1.  Antidepressants and the developing nervous system.

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 2.  A role for the serotonin reuptake transporter in the brain and intestinal features of autism spectrum disorders and developmental antidepressant exposure.

Authors:  Kara Gross Margolis
Journal:  J Chem Neuroanat       Date:  2017-02-14       Impact factor: 3.052

3.  Prenatal antidepressant exposures and gastrointestinal complaints in childhood: A gut-brain axis connection?

Authors:  Amy L Salisbury; George D Papandonatos; Laura R Stroud; Alicia K Smith; Patricia A Brennan
Journal:  Dev Psychobiol       Date:  2020-03-13       Impact factor: 3.038

Review 4.  Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.

Authors:  Tamar L Gur; Deborah R Kim; C Neill Epperson
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

5.  Methodological challenges in using routinely collected health data to investigate long-term effects of medication use during pregnancy.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Ther Adv Drug Saf       Date:  2013-02

Review 6.  Gene-environment interactions and the enteric nervous system: Neural plasticity and Hirschsprung disease prevention.

Authors:  Robert O Heuckeroth; Karl-Herbert Schäfer
Journal:  Dev Biol       Date:  2016-03-17       Impact factor: 3.582

Review 7.  Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review.

Authors:  Hanan El Marroun; Tonya White; Frank C Verhulst; Henning Tiemeier
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-05-27       Impact factor: 4.785

Review 8.  Novel aspects of enteric serotonergic signaling in health and brain-gut disease.

Authors:  Andrew Del Colle; Narek Israelyan; Kara Gross Margolis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-04       Impact factor: 4.052

Review 9.  Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.

Authors:  Natalie Terry; Kara Gross Margolis
Journal:  Handb Exp Pharmacol       Date:  2017

Review 10.  Medical and psychological risks and consequences of long-term opioid therapy in women.

Authors:  Beth D Darnall; Brett R Stacey; Roger Chou
Journal:  Pain Med       Date:  2012-08-20       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.